Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
05 Gennaio 2024 - 2:01PM
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced business updates,
its expected 2024 milestones and its upcoming presentation at the
42nd Annual J.P. Morgan Healthcare Conference.
“Mersana’s next-generation ADC platforms are designed to
overcome key limitations of traditional ADCs,” said Martin Huber,
M.D., President and Chief Executive Officer of Mersana
Therapeutics. “We gained important new learnings in 2023 that
affirmed the differentiation of both Dolasynthen, our
next-generation cytotoxic ADC platform, and Immunosynthen, our
STING-agonist ADC platform.
“In 2024, we plan to demonstrate over several data presentations
how Dolasynthen’s preclinical differentiation translates into the
clinic. These presentations will include initial clinical data from
our ongoing Phase 1 clinical trial of XMT-1660. We also are looking
forward to progressing dose escalation in our Phase 1 clinical
trial of XMT-2056 as we strive to advance ADCs beyond cytotoxics by
enabling targeted innate immune stimulation via our Immunosynthen
platform,” Dr. Huber continued. “With these programs in motion,
multiple collaborations in place and a strong balance sheet,
Mersana is well positioned to meaningfully advance its mission to
discover and develop life-changing ADCs for patients fighting
cancer.”
Business Updates and Expected Milestones
- XMT-1660: Mersana
continues to advance its Phase 1 clinical trial of XMT-1660, the
company’s lead Dolasynthen ADC candidate targeting B7-H4. The trial
is currently enrolling patients in dose escalation at dose level 6
as well as in backfill cohorts to optimize dose and schedule.
Mersana plans to initiate tumor-specific expansion cohorts in the
second quarter of 2024 and share initial dose escalation and
backfill cohort data in mid-2024.
- XMT-2056: Mersana
is restarting its Phase 1 clinical trial of XMT-2056, the company's
lead Immunosynthen ADC candidate targeting a novel HER2 epitope.
The company plans to advance dose escalation in 2024. XMT-2056 is
wholly owned by Mersana. GSK plc has an exclusive global license
option to co-develop and commercialize the candidate.
- Additional Upcoming Data
Presentations: In the first half of 2024, Mersana expects
to present data at multiple scientific meetings demonstrating
Dolasynthen’s differentiation from first-generation cytotoxic ADC
platforms. The presentations will include clinical data from two
discontinued ADC candidates, XMT-1592 and XMT-1536 (UpRi).
- Collaborations:
Mersana continues to advance its collaborations with Janssen
Biotech, Inc. and Merck KGaA, Darmstadt, Germany. The collaboration
and license agreement with Janssen focuses on discovering novel
Dolasynthen ADCs for up to three targets. The collaboration and
license agreement with Merck KGaA, Darmstadt, Germany focuses on
discovering novel Immunosynthen ADCs for up to two targets. In
2023, Mersana received development milestone payments from both
collaborations.
- Financial Resources: Mersana’s cash, cash
equivalents and marketable securities as of September 30, 2023 were
$241.0 million. The company continues to expect that its available
funds will be sufficient to support its current operating plan
commitments into 2026.
Upcoming J.P. Morgan Healthcare Conference Presentation
and WebcastMersana President and CEO Dr. Martin Huber will
present at the 42nd Annual J.P. Morgan Healthcare Conference on
Thursday, January 11, 2024 at 2:15 p.m. Eastern Time/11:15 a.m.
Pacific Time. A live webcast of this event will be available on the
Investors & Media section of Mersana’s website at
www.mersana.com. An archived replay will be available for
approximately 90 days following the event.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company focused on the
development of novel antibody-drug conjugates (ADCs) and driven by
the knowledge that patients are waiting for new treatment options.
The company has developed proprietary cytotoxic (Dolasynthen) and
immunostimulatory (Immunosynthen) ADC platforms that are generating
a pipeline of wholly-owned and partnered product candidates with
the potential to treat a range of cancers. Its pipeline includes
XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an
Immunosynthen ADC targeting a novel epitope of human epidermal
growth factor receptor 2 (HER2). Mersana routinely posts
information that may be useful to investors on the “Investors &
Media” section of its website at www.mersana.com.
Forward-Looking StatementsThis press release
contains “forward-looking” statements and information within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by words such as “aims,”
“anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”
“potential,” “seeks,” “will” and variations of these words or
similar expressions, although not all forward-looking statements
contain these words. Forward-looking statements in this press
release include, but are not limited to, statements concerning
Mersana’s strategic priorities; its plans regarding the clinical
development of XMT-1660 and XMT-2056, including with respect to the
resumption of Mersana’s Phase 1 clinical trial of XMT-2056 and the
progress and design of the clinical trials of these product
candidates; Mersana’s planned data presentations, including with
respect to its Phase 1 clinical trial of XMT-1660; Mersana’s cash
runway; Mersana’s collaborations with third parties; and the
development and potential of Mersana’s product candidates,
platforms, technology and pipeline of ADC candidates. Mersana may
not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking
statements as a result of various factors, including, among other
things, uncertainties inherent in research and development, in the
advancement, progression and completion of clinical trials and in
the clinical development of Mersana’s product candidates, including
XMT-1660 and XMT-2056; the risk that Mersana may face delays in
resuming its Phase 1 clinical trial of XMT-2056; the risk that
Mersana may not realize the intended benefits of its platforms,
technology and collaborations; and other important factors, any of
which could cause Mersana’s actual results to differ from those
contained in the forward-looking statements, that are described in
greater detail in the section entitled “Risk Factors” in Mersana’s
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (“SEC”) on November 7, 2023, as well as in
other filings Mersana may make with the SEC in the future. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Mersana expressly disclaims any
obligation to update any forward-looking statements contained
herein, whether because of any new information, future events,
changed circumstances or otherwise, except as otherwise required by
law.
Contact:Jason Fredette
617-498-0020jason.fredette@mersana.com
Grafico Azioni Mersana Therapeutics (NASDAQ:MRSN)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Mersana Therapeutics (NASDAQ:MRSN)
Storico
Da Mag 2023 a Mag 2024